EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Nintedanib in progressive fibrosing hypersensitivity pneumonitis: Real-world effects on lung function and survival

Inês Carvalho iD, Mariana Ribeiro, Pedro Sá, André Carvalho, Claúdia Camila Dias, David Coelho, André Terras Alexandre, Hélder Novais E Bastos, António Morais, Natália Melo, Patrícia Caetano Mota

Therapeutic Advances in Respiratory Disease · 2026

DOI: 10.1177/17534666261488263 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Inês Carvalho und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, Unidade Local de Saúde São João, Porto, Portugal. Hauptthemen laut MEDLINE: Indoles, Alveolitis, Extrinsic Allergic, Immunosuppressive Agents, Lung. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fibrotic hypersensitivity pneumonitis (f-HP) may progress despite antigen avoidance and immunosuppressive therapy. Although nintedanib is approved for progressive pulmonary fibrosis (PPF), real-world evidence regarding its effectiveness and safety in f-HP, particularly when combined with immunosuppression, remains limited.

Objectives

To compare lung function trajectories, survival, and treatment safety in patients with progressive f-HP treated with nintedanib plus immunosuppressive therapy versus immunosuppressive therapy alone.

Design

Retrospective, single-center cohort study with a historical control group.

Methods

Patients with a multidisciplinary diagnosis of f-HP who fulfilled the INBUILD criteria for PPF were included. Patients treated with nintedanib were compared with patients managed with immunosuppressive therapy alone. Longitudinal changes in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) over 24 months were analysed using linear mixed-effects models. Survival was assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards regression.

Results

A total of 106 patients were included, of whom 54 received nintedanib and 52 received immunosuppressive therapy alone. Baseline characteristics were broadly comparable between groups. No statistically significant differences were observed in FVC or DLCO trajectories over 24 months, although a modest numerical trend towards relative FVC stabilisation was observed in the nintedanib group. Median survival from disease progression was longer in nintedanib-treated patients than in those not receiving antifibrotic therapy (178 vs 78 months; log-rank p = 0.001). In multivariable analysis, nintedanib use remained independently associated with improved survival (p = 0.013). Gastrointestinal adverse events were more frequent with nintedanib but were generally mild to moderate, and treatment discontinuation due to intolerance occurred in 7.4% of patients.

Conclusion

In this real-world cohort of patients with progressive f-HP, nintedanib treatment was associated with longer survival despite similar lung function trajectories compared with immunosuppressive therapy alone, and had a manageable safety profile. Given the retrospective design and use of historical controls, the observed survival association should be interpreted cautiously and requires confirmation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesAlveolitis, Extrinsic AllergicImmunosuppressive AgentsLungPulmonary FibrosisProtein Kinase InhibitorsHumansFemaleMaleDisease ProgressionVital CapacityTreatment OutcomeRetrospective StudiesMiddle AgedAgedTime FactorsDrug Therapy, CombinationKaplan-Meier Estimate

Stichwörter der Autor:innen

fibrotic hypersensitivity pneumonitisnintedanibprogressive pulmonary fibrosissurvival

Substanzen

nintedanibIndolesImmunosuppressive AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Pulmonology Department, Unidade Local de Saúde São João, Porto, Portugal.
  • Radiology Department, Unidade Local de Saúde de São João, Porto, Portugal.
  • Faculty of Medicine, University of Porto (FMUP), Instituto de Investigação e Inovação Em Saúde, Porto, Portugal.
  • Central Management Resources: Knowledge Management Unit, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal.
  • RISE-Health, Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal.

ORCID-Profile: Inês Carvalho

Zitieren

APA

Carvalho, I., Ribeiro, M., Sá, P., Carvalho, A., Dias, C. C., Coelho, D., Alexandre, A. T., E Bastos, H. N., Morais, A., Melo, N., & Mota, P. C. (2026). Nintedanib in progressive fibrosing hypersensitivity pneumonitis: Real-world effects on lung function and survival. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261488263

Vancouver

Carvalho I, Ribeiro M, Sá P, Carvalho A, Dias CC, Coelho D, et al. Nintedanib in progressive fibrosing hypersensitivity pneumonitis: Real-world effects on lung function and survival. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261488263

BibTeX
@article{Carvalho2026,
  author = {Carvalho, Inês and Ribeiro, Mariana and Sá, Pedro and Carvalho, André and Dias, Claúdia Camila and Coelho, David and Alexandre, André Terras and E Bastos, Hélder Novais and Morais, António and Melo, Natália and Mota, Patrícia Caetano},
  title = {Nintedanib in progressive fibrosing hypersensitivity pneumonitis: Real-world effects on lung function and survival},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  doi = {10.1177/17534666261488263}
}
Kostenlos starten →